STAT: The FDA needs a risk evaluation and mitigation strategy for Alzheimer’s drug lecanemab
Eisai’s Leqembi: Addressing the risks, benefits of Alzheimer's drug
https://www.statnews.com/2023/06/16...ation-strategy-for-alzheimers-drug-lecanemab/
As an Alzheimer’s expert, I’m both optimistic and worried about lecanemab and donanemab. The health care system isn't ready.
Eisai’s Leqembi: Addressing the risks, benefits of Alzheimer's drug
https://www.statnews.com/2023/06/16...ation-strategy-for-alzheimers-drug-lecanemab/
As an Alzheimer’s expert, I’m both optimistic and worried about lecanemab and donanemab. The health care system isn't ready.